Eliem Therapeutics (NASDAQ:ELYM) Trading Up 1.1% – Time to Buy?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) shot up 1.1% during trading on Wednesday . The stock traded as high as $13.71 and last traded at $13.42. Approximately 1,452,967 shares were traded during mid-day trading, an increase of 199% from the average daily volume of 486,688 shares. The stock had previously closed at $13.27.

Eliem Therapeutics Stock Performance

The stock has a market capitalization of $399.27 million, a PE ratio of -25.32 and a beta of -0.39. The stock has a 50-day moving average price of $11.38 and a two-hundred day moving average price of $7.91.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.

The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.